Valeant Pharmaceuticals International Inc (VRX): Today's Featured Drugs Winner

Valeant Pharmaceuticals International ( VRX) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 1.7%. By the end of trading, Valeant Pharmaceuticals International rose $1.92 (2.2%) to $88.00 on average volume. Throughout the day, 1,792,869 shares of Valeant Pharmaceuticals International exchanged hands as compared to its average daily volume of 1,971,100 shares. The stock ranged in a price between $86.89-$89.25 after having opened the day at $87.21 as compared to the previous trading day's close of $86.08. Other companies within the Drugs industry that increased today were: Onyx Pharmaceuticals ( ONXX), up 51.3%, Bacterin International Holdings ( BONE), up 20.0%, Prima Biomed ( PBMD), up 18.9% and Oxygen Biotherapeutics ( OXBT), up 18.2%.

Valeant Pharmaceuticals International, Inc., a specialty pharmaceutical company, develops, manufactures, and markets pharmaceutical products and medical devices in the areas of neurology, dermatology, and branded generics. Valeant Pharmaceuticals International has a market cap of $28.6 billion and is part of the health care sector. Shares are up 44.0% year to date as of the close of trading on Friday. Currently there are 9 analysts that rate Valeant Pharmaceuticals International a buy, 1 analyst rates it a sell, and 3 rate it a hold.

TheStreet Ratings rates Valeant Pharmaceuticals International as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and generally higher debt management risk.

On the negative front, Mast Therapeutics ( MSTX), down 38.6%, Insmed ( INSM), down 18.7%, TherapeuticsMD ( TXMD), down 13.5% and KaloBios Pharmaceuticals ( KBIO), down 7.2% , were all laggards within the drugs industry with Amgen ( AMGN) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.
null

If you liked this article you might like

ADP Is Morphing Into the IBM Blob: Bill Ackman

Follow the Crucial '$20 Level Rule' When Trading Stocks

$20 Should Be Your Cutoff Point

Short the Stocks That Fall Below $20

One of the Most Recognized Hedge Fund Managers Has Had a Terrible Year